bevacizumab + capecitabine + docetaxel

The combination of bevacizumab, capecitabine, and docetaxel is a triplet therapy regimen used primarily in oncology. This combination has been studied in various clinical settings, particularly for breast cancer treatment. ## Mechanism and Clinical Use This triplet therapy combines three distinct mechanisms of action: 1. **Bevacizumab** is a monoclonal antibody that targets vascular endothelial growth factor (VEGF-A), inhibiting angiogenesis by preventing VEGF-A from interacting with its receptors[3]. This suppresses neovascularization, which is crucial for tumor growth. 2. **Capecitabine** is an oral fluoropyrimidine that converts to 5-fluorouracil in tumor tissues, interfering with DNA synthesis and cell division. 3. **Docetaxel** is a taxane that works by disrupting microtubule function, which is essential for cell division, thereby inhibiting cancer cell growth. The combination has been studied in both metastatic breast cancer and as neoadjuvant therapy for locally advanced breast cancer, showing promising efficacy profiles[1][6]. ## Clinical Evidence In the NCCTG N0432 study, this triplet therapy produced a response rate of 49% in metastatic breast cancer patients, with median overall survival of 28.4 months and progression-free survival of 11.1 months[1]. The clinical benefit rate (responses plus stable disease >6 months) was 69%. As neoadjuvant therapy for HER2-negative invasive breast cancer, the combination achieved a pathologic complete response rate of 22% and an overall clinical response rate of 72%[6]. The regimen also facilitated breast-conserving surgery in 83% of patients. ## Safety Profile The combination is moderately well tolerated but requires careful management of side effects. Common adverse events include: - Myelosuppression requiring growth factor support in some patients - Hand-foot syndrome (particularly associated with capecitabine) - Diarrhea and mucositis - Hypertension (associated with bevacizumab) Dose reductions of docetaxel and/or capecitabine are often necessary to manage toxicities[1][5]. However, the addition of bevacizumab does not appear to significantly increase docetaxel or capecitabine-related adverse events[1]. This triplet therapy represents an important treatment option for selected breast cancer patients, particularly those with metastatic disease or locally advanced tumors requiring neoadjuvant therapy.

Brand names

TaxotereXelodaAvastin

Other names

docetaxel + capecitabine + bevacizumab